Hedge funds ramp up short positions on Hims & Hers ahead of Wegovy dispute
Hedge funds increased short bets against Hims & Hers Health in January to levels not seen in at least a year, according to Hazeltree data provided to Reuters. The rise in short interest preceded a sequence of events that included Hims withdrawing a low-cost version of Novo Nordisk’s weight-loss drug under FDA scrutiny, a patent lawsuit from Novo No…